

BIO-TECHNE Corp  
Form 8-K  
June 08, 2015  
**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): June 8, 2015

**BIO-TECHNE CORPORATION**

(Exact Name of Registrant as Specified in Charter)

**Minnesota**

(State or Other Jurisdiction of Incorporation)

**0-17272**

(Commission File Number)

**41-1427402**

(I.R.S. Employer

Identification No.)

**614 McKinley Place NE**

**Minneapolis, MN 55413**

(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: **(612) 379-8854**

**Not Applicable**

(Former Name or Former Address, if changed since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01 Other Events**

On June 4, 2015, Bio-Techne Corporation entered into an agreement to acquire 100% of the equity of Cliniqua Corporation. A copy of the press release issued by Bio-Techne Corporation on June 5, 2015 relating thereto is attached as Exhibit 99.1.

**Item 9.01 Financial Statements and Exhibits.**

(a) Financial statements: None

(b) Pro forma financial information: None

(c) Shell Company Transactions: None

(d) Exhibits:

99.1 Press Release, dated June 5, 2015, announcing entry into an agreement to acquire Cliniqua Corporation.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: June 8, 2015

**BIO-TECHNE CORPORATION**

/s/ Charles R. Kummeth  
Charles R. Kummeth  
President and Chief Executive Officer

---

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**BIO-TECHNE CORPORATION**

**EXHIBIT INDEX TO FORM 8-K**

Date of Report: June 8, 2015    Commission File No.: 0-17272

**Exhibit No.   ITEM**

99.1 Press Release, dated June 5, 2015, regarding acquisition of Cliniqa Corporation